Breaking News, Collaborations & Alliances

Emergent, AstraZeneca Ink Large-Scale Mfg. Pact

Will expand manufacturing for COVID-19 vaccine candidate, AZD1222.

By: Contract Pharma

Contract Pharma Staff

Emergent BioSolutions Inc. has signed an agreement to provide contract development and manufacturing (CDMO) services for large-scale commercial drug substance manufacturing for AstraZeneca’s COVID-19 vaccine candidate, AZD1222. The agreement is valued at approximately $174 million through 2021.   The adenovirus vector-based vaccine candidate, AZD1222, was co-invented by the University of Oxford and its spin-out company, Vaccitech, and licensed by AstraZeneca. It is currently in clinical trials...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters